Covid-19 vaccine developed by US based Moderna might be the second candidate to get emergency use authorisation. According to US regulators, Moderna’s vaccine is safe and highly effective. Therefore, the Food and Drugs Administration is considering to grant the vaccine emergency approval in US, the sources familiar with the topic said.
The FDA said its analysis “supported a favorable safety profile, with no specific safety concerns identified that would preclude issuance of an emergency use authorization.”
According to the report by FDA, Moderna’s vaccine begins immunisation process just about 10 days after the first of two shot. It follows the same two-day regime followed by Pfizer and BioNTech’s vaccine which received emergency approval last week.
The FDA report said: “The two-dose vaccination regimen was highly effective in preventing PCR-confirmed Covid-19 occurring at least 14 days after receipt of the second dose.”
The US rolled out vaccination drive on Monday and approval of a second vaccine in the country where the virus has killed more than 300,000 people would only raise hope among people.
According to a Financial Times report, Moderna’s vaccine can also be the first of its kinds to show results among asymptomatic patients.
Moderna had released its analysis last month wherein its vaccine candidate was proved to be at least 94.1 per cent effective in a trial of about 30,000 participants. However, the efficacy rate was lower among the people aged above 65 at 86.4 per cent.
Earlier this year, the U.S. government signed deals with Moderna and Pfizer to acquire 200 million doses in the first quarter of 2021.
Pfizer’s vaccine was expected to be prized at $25, however, the Trump administration recently announced that everyone in the US will be getting free shots of covid-19 vaccine.
However, in a recently concluded survey, it was shown that around 21 per cent of young adults have said that they don’t trust vaccine and will likely not administer one even for free.